Top

Published in:

01-02-2012 | Focussed Research Review

Novel insights into the molecular mechanisms of HLA class I abnormalities

Author: Barbara Seliger

Published in: Cancer Immunology, Immunotherapy | Issue 2/2012

Abstract

Alterations in the MHC class I surface antigens represent one mechanism of tumor cells to escape from natural or immunotherapy-induced antitumor immune responses. In order to restore MHC class I expression, knowledge about the underlying molecular mechanisms of MHC class I defects in different tumor types is required. In most cases, abnormalities of MHC class I expression are reversible by cytokines suggesting a deregulation rather than structural abnormalities of members of the antigen-processing and presentation machinery (APM). The impaired expression of APM components could be controlled at the epigenetic, transcriptional and/or posttranscriptional level. Furthermore, a direct link between altered transcription factor binding, interferon signal transduction and MHC class I APM component expression has been shown, which might be further associated with cell cycle progression. This information will not only give novel insights into the (patho) physiology of the antigen-processing and presenting pathway, but will help in the future to design effective T cell-based immunotherapies.

Nagaraj S, Gabrilovich DI (2010) Myeloid-derived suppressor cells in human cancer. Cancer J 16(4):348–353. doi:10.1097/PPO.0b013e3181eb3358 PubMedCrossRef

Lu T, Ramakrishnan R, Altiok S, Youn JI, Cheng P, Celis E, Pisarev V, Sherman S, Sporn MB, Gabrilovich D (2011) Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. J Clin Invest. doi:10.1172/JCI45862

Scholz C, Tampe R (2009) The peptide-loading complex—antigen translocation and MHC class I loading. Biol Chem 390(8):783–794. doi:10.1515/BC.2009.069 PubMedCrossRef

Ferrone S, Marincola FM (1995) Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 16(10):487–494PubMedCrossRef

Campoli M, Ferrone S (2008) HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene 27(45):5869–5885. doi:10.1038/onc.2008.273 PubMedCrossRef

Aptsiauri N, Carretero R, Garcia-Lora A, Real LM, Cabrera T, Garrido F (2008) Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations. Cancer Immunol Immunother 57(11):1727–1733. doi:10.1007/s00262-008-0532-3 PubMedCrossRef

Seliger B (2008) Molecular mechanisms of MHC class I abnormalities and APM components in human tumors. Cancer Immunol Immunother 57(11):1719–1726PubMedCrossRef

Garrido F, Algarra I, Garcia-Lora AM (2010) The escape of cancer from T lymphocytes: immunoselection of MHC class I loss variants harboring structural-irreversible “hard” lesions. Cancer Immunol Immunother 59(10):1601–1606. doi:10.1007/s00262-010-0893-2 PubMedCrossRef

Garrido C, Algarra I, Maleno I, Stefanski J, Collado A, Garrido F, Garcia-Lora AM (2010) Alterations of HLA class I expression in human melanoma xenografts in immunodeficient mice occur frequently and are associated with higher tumorigenicity. Cancer Immunol Immunother 59(1):13–26. doi:10.1007/s00262-009-0716-5 PubMedCrossRef

10.

Seliger B, Schreiber K, Delp K, Meissner M, Hammers S, Reichert T, Pawlischko K, Tampe R, Huber C (2001) Downregulation of the constitutive tapasin expression in human tumor cells of distinct origin and its transcriptional upregulation by cytokines. Tissue Antigens 57(1):39–45PubMedCrossRef

11.

Restifo NP, Esquivel F, Kawakami Y, Yewdell JW, Mule JJ, Rosenberg SA, Bennink JR (1993) Identification of human cancers deficient in antigen processing. J Exp Med 177(2):265–272PubMedCrossRef

12.

Cabrera CM, Lopez-Nevot MA, Jimenez P, Garrido F (2005) Involvement of the chaperone tapasin in HLA-B44 allelic losses in colorectal tumors. Int J Cancer 113(4):611–618. doi:10.1002/ijc.20526 PubMedCrossRef

13.

Seliger B, Ritz U, Abele R, Bock M, Tampe R, Sutter G, Drexler I, Huber C, Ferrone S (2001) Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. Cancer Res 61(24):8647–8650PubMed

14.

Kamphausen E, Kellert C, Abbas T, Akkad N, Tenzer S, Pawelec G, Schild H, van Endert P, Seliger B (2010) Distinct molecular mechanisms leading to deficient expression of ER-resident aminopeptidases in melanoma. Cancer Immunol Immunother 59(8):1273–1284. doi:10.1007/s00262-010-0856-7 PubMedCrossRef

15.

Atkins D, Breuckmann A, Schmahl GE, Binner P, Ferrone S, Krummenauer F, Storkel S, Seliger B (2004) MHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma. Int J Cancer 109(2):265–273. doi:10.1002/ijc.11681 PubMedCrossRef

16.

Meissner M, Reichert TE, Kunkel M, Gooding W, Whiteside TL, Ferrone S, Seliger B (2005) Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clin Cancer Res 11(7):2552–2560. doi:10.1158/1078-0432.CCR-04-2146 PubMedCrossRef

17.

Yang T, McNally BA, Ferrone S, Liu Y, Zheng P (2003) A single-nucleotide deletion leads to rapid degradation of TAP-1 mRNA in a melanoma cell line. J Biol Chem 278(17):15291–15296. doi:10.1074/jbc.M300954200 PubMedCrossRef

18.

Yang T, Lapinski PE, Zhao H, Zhou Q, Zhang H, Raghavan M, Liu Y, Zheng P (2005) A rare transporter associated with antigen processing polymorphism overpresented in HLAlow colon cancer reveals the functional significance of the signature domain in antigen processing. Clin Cancer Res 11(10):3614–3623. doi:10.1158/1078-0432.CCR-04-1804 PubMedCrossRef

19.

Vermeulen CF, Jordanova ES, ter Haar NT, Kolkman-Uljee SM, de Miranda NF, Ferrone S, Peters AA, Fleuren GJ (2007) Expression and genetic analysis of transporter associated with antigen processing in cervical carcinoma. Gynecol Oncol 105(3):593–599. doi:10.1016/j.ygyno.2007.02.016 PubMedCrossRef

20.

Maleno I, Lopez-Nevot MA, Cabrera T, Salinero J, Garrido F (2002) Multiple mechanisms generate HLA class I altered phenotypes in laryngeal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Cancer Immunol Immunother 51(7):389–396. doi:10.1007/s00262-002-0296-0 PubMedCrossRef

21.

Hayashi T, Kobayashi Y, Kohsaka S, Sano K (2006) The mutation in the ATP-binding region of JAK1, identified in human uterine leiomyosarcomas, results in defective interferon-gamma inducibility of TAP1 and LMP2. Oncogene 25(29):4016–4026PubMedCrossRef

22.

Chen HL, Gabrilovich D, Tampe R, Girgis KR, Nadaf S, Carbone DP (1996) A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer. Nat Genet 13(2):210–213. doi:10.1038/ng0696-210 PubMedCrossRef

23.

Chang CC, Ogino T, Mullins DW, Oliver JL, Yamshchikov GV, Bandoh N, Slingluff CL Jr, Ferrone S (2006) Defective human leukocyte antigen class I-associated antigen presentation caused by a novel beta2-microglobulin loss-of-function in melanoma cells. J Biol Chem 281(27):18763–18773. doi:10.1074/jbc.M511525200 PubMedCrossRef

24.

Cabrera CM, Jimenez P, Cabrera T, Esparza C, Ruiz-Cabello F, Garrido F (2003) Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: beta2-microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors. Tissue Antigens 61(3):211–219PubMedCrossRef

25.

Seliger B, Bock M, Ritz U, Huber C (2002) High frequency of a non-functional TAP1/LMP2 promoter polymorphism in human tumors. Int J Oncol 20(2):349–353PubMed

26.

Hodson I, Bock M, Ritz U, Brenner W, Huber C, Seliger B (2003) Analysis of the structural integrity of the TAP2 gene in renal cell carcinoma. Int J Oncol 23(4):991–999PubMed

27.

Qin Z, Schwartzkopff J, Pradera F, Kammertoens T, Seliger B, Pircher H, Blankenstein T (2003) A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells. Cancer Res 63(14):4095–4100PubMed

28.

Kallfelz M, Jung D, Hilmes C, Knuth A, Jaeger E, Huber C, Seliger B (1999) Induction of immunogenicity of a human renal-cell carcinoma cell line by TAP1-gene transfer. Int J Cancer 81(1):125–133. doi:10.1002/(SICI)1097-0215(19990331)81:1<125::AID-IJC21>3.0.CO;2-2 PubMedCrossRef

29.

Verweij MC, Koppers-Lalic D, Loch S, Klauschies F, de la Salle H, Quinten E, Lehner PJ, Mulder A, Knittler MR, Tampe R, Koch J, Ressing ME, Wiertz EJ (2008) The varicellovirus UL49.5 protein blocks the transporter associated with antigen processing (TAP) by inhibiting essential conformational transitions in the 6 + 6 transmembrane TAP core complex. J Immunol 181(7):4894–4907

30.

Oosten LE, Koppers-Lalic D, Blokland E, Mulder A, Ressing ME, Mutis T, van Halteren AG, Wiertz EJ, Goulmy E (2007) TAP-inhibiting proteins US6, ICP47 and UL49.5 differentially affect minor and major histocompatibility antigen-specific recognition by cytotoxic T lymphocytes. Int Immunol 19(9):1115–1122. doi:10.1093/intimm/dxm082

31.

Koppers-Lalic D, Verweij MC, Lipinska AD, Wang Y, Quinten E, Reits EA, Koch J, Loch S, Marcondes Rezende M, Daus F, Bienkowska-Szewczyk K, Osterrieder N, Mettenleiter TC, Heemskerk MH, Tampe R, Neefjes JJ, Chowdhury SI, Ressing ME, Rijsewijk FA, Wiertz EJ (2008) Varicellovirus UL 49.5 proteins differentially affect the function of the transporter associated with antigen processing, TAP. PLoS Pathog 4(5):e1000080PubMedCrossRef

32.

Griffin BD, Verweij MC, Wiertz EJ (2010) Herpesviruses and immunity: the art of evasion. Vet Microbiol 143(1):89–100. doi:10.1016/j.vetmic.2010.02.017 PubMedCrossRef

33.

Croft NP, Shannon-Lowe C, Bell AI, Horst D, Kremmer E, Ressing ME, Wiertz EJ, Middeldorp JM, Rowe M, Rickinson AB, Hislop AD (2009) Stage-specific inhibition of MHC class I presentation by the Epstein-Barr virus BNLF2a protein during virus lytic cycle. PLoS Pathog 5(6):e1000490. doi:10.1371/journal.ppat.1000490

34.

Rodriguez T, Mendez R, Del Campo A, Jimenez P, Aptsiauri N, Garrido F, Ruiz-Cabello F (2007) Distinct mechanisms of loss of IFN-gamma mediated HLA class I inducibility in two melanoma cell lines. BMC Cancer 7:34. doi:10.1186/1471-2407-7-34 PubMedCrossRef

35.

Respa A, Bukur J, Ferrone S, Pawelec G, Zhao Y, Wang E, Marincola FM, Seliger B (2011) Association of IFN-gamma signal transduction defects with impaired HLA class I antigen processing in melanoma cell lines. Clin Cancer Res 17(9):2668–2678PubMedCrossRef

36.

Setiadi AF, Omilusik K, David MD, Seipp RP, Hartikainen J, Gopaul R, Choi KB, Jefferies WA (2008) Epigenetic enhancement of antigen processing and presentation promotes immune recognition of tumors. Cancer Res 68(23):9601–9607PubMedCrossRef

37.

Setiadi AF, David MD, Seipp RP, Hartikainen JA, Gopaul R, Jefferies WA (2007) Epigenetic control of the immune escape mechanisms in malignant carcinomas. Mol Cell Biol 27(22):7886–7894PubMedCrossRef

38.

Sers C, Kuner R, Falk CS, Lund P, Sueltmann H, Braun M, Buness A, Ruschhaupt M, Conrad J, Mang-Fatehi S, Stelniec I, Krapfenbauer U, Poustka A, Schafer R (2009) Down-regulation of HLA Class I and NKG2D ligands through a concerted action of MAPK and DNA methyltransferases in colorectal cancer cells. Int J Cancer 125(7):1626–1639. doi:10.1002/ijc.24557 PubMedCrossRef

39.

Khan AN, Gregorie CJ, Tomasi TB (2008) Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells. Cancer Immunol Immunother 57(5):647–654. doi:10.1007/s00262-007-0402-4 PubMedCrossRef

40.

Epperson DE, Arnold D, Spies T, Cresswell P, Pober JS, Johnson DR (1992) Cytokines increase transporter in antigen processing-1 expression more rapidly than HLA class I expression in endothelial cells. J Immunol 149(10):3297–3301PubMed

41.

Vertegaal AC, Kuiperij HB, Houweling A, Verlaan M, van der Eb AJ, Zantema A (2003) Differential expression of tapasin and immunoproteasome subunits in adenovirus type 5- versus type 12-transformed cells. J Biol Chem 278(1):139–146. doi:10.1074/jbc.M206267200 PubMedCrossRef

42.

Seliger B, Harders C, Lohmann S, Momburg F, Urlinger S, Tampe R, Huber C (1998) Down-regulation of the MHC class I antigen-processing machinery after oncogenic transformation of murine fibroblasts. Eur J Immunol 28(1):122–133. doi:10.1002/(SICI)1521-4141(199801)28:01<122::AID-IMMU122>3.0.CO;2-F PubMedCrossRef

43.

Herrmann F, Lehr HA, Drexler I, Sutter G, Hengstler J, Wollscheid U, Seliger B (2004) HER-2/neu-mediated regulation of components of the MHC class I antigen-processing pathway. Cancer Res 64(1):215–220PubMedCrossRef

44.

Griffioen M, Peltenburg LT, van Oorschot DA, Schrier PI (1995) C-myc represses transiently transfected HLA class I promoter sequences not locus-specifically. Immunobiology 193(2–4):238–247PubMedCrossRef

45.

Ashrafi GH, Tsirimonaki E, Marchetti B, O’Brien PM, Sibbet GJ, Andrew L, Campo MS (2002) Down-regulation of MHC class I by bovine papillomavirus E5 oncoproteins. Oncogene 21(2):248–259. doi:10.1038/sj.onc.1205008 PubMedCrossRef

46.

Mimura K, Ando T, Poschke I, Mougiakakos D, Johansson CC, Ichikawa J, Okita R, Nishimura MI, Handke D, Krug N, Choudhury A, Seliger B, Kiessling R (2011) T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2. Int J Cancer 128(2):390–401PubMedCrossRef

47.

Choudhury A, Charo J, Parapuram SK, Hunt RC, Hunt DM, Seliger B, Kiessling R (2004) Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. Int J Cancer 108(1):71–77. doi:10.1002/ijc.11497 PubMedCrossRef

48.

Zheng P, Guo Y, Niu Q, Levy DE, Dyck JA, Lu S, Sheiman LA, Liu Y (1998) Proto-oncogene PML controls genes devoted to MHC class I antigen presentation. Nature 396(6709):373–376. doi:10.1038/24628 PubMedCrossRef

49.

Zhang H, Melamed J, Wei P, Cox K, Frankel W, Bahnson RR, Robinson N, Pyka R, Liu Y, Zheng P (2003) Concordant down-regulation of proto-oncogene PML and major histocompatibility antigen HLA class I expression in high-grade prostate cancer. Cancer Immun 3:2PubMed

50.

Bukur J, Herrmann F, Handke D, Recktenwald C, Seliger B (2010) Identification of E2F1 as an important transcription factor for the regulation of tapasin expression. J Biol Chem 285(40):30419–30426PubMedCrossRef

Title: Novel insights into the molecular mechanisms of HLA class I abnormalities
Author: Barbara Seliger
Publication date: 01-02-2012
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 2/2012
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-011-1153-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2012

Potential rescue, survival and differentiation of cancer stem cells and primary non-transformed stem cells by monocyte-induced split anergy in natural killer cells

Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin

Interleukin 6 mediates production of interleukin 10 in metastatic melanoma

Exposure of CD34+ precursors to cytostatic anthraquinone-derivatives induces rapid dendritic cell differentiation: implications for cancer immunotherapy

Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients

Overcoming immunosuppression in the melanoma microenvironment induced by chronic inflammation

Keynote webinar | Spotlight on antibody–drug conjugates in cancer